Designation of Teduglutide (Revestive) as an orphan drug - Shire Australia

Overview

The Therapeutic Goods Act 1989 was enacted to provide a framework for regulating therapeutic goods in Australia, ensuring that these goods are safe, of high quality, and effective. This legislation was introduced to address the need for a comprehensive regulatory system to oversee the manufacturing, importation, advertising, and supply of therapeutic goods. Enacted by the Australian Parliament, the Act aims to protect public health by ensuring that therapeutic goods are appropriately regulated and that they meet necessary standards. The policy objective of the Act is to facilitate access to therapeutic goods that are safe and effective while also ensuring that the health and safety of the Australian public are paramount. In the context of orphan drugs, the Therapeutic Goods Act 1989 empowers the Therapeutic Goods Administration to designate certain drugs as orphan drugs, encouraging the research and development of treatments for rare conditions that might otherwise be neglected due to limited commercial viability. The designation of Teduglutide (REVESTIVE) as an orphan drug for the treatment of Short Bowel Syndrome in adults dependent on parenteral support exemplifies the Act's role in addressing specific health needs that are not adequately met by existing treatments. This designation, made by the Delegate of the Secretary under the Therapeutic Goods Regulations 1990, underscores the commitment to providing therapeutic options for rare and debilitating conditions.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, applies to a broad range of therapeutic goods, including medicines, medical devices, and blood products, among others. In the context of the designation of Teduglutide (REVESTIVE) as an orphan drug, this legislation specifically applies to the treatment of rare conditions and ensures that there are appropriate mechanisms for the development, evaluation, and registration of therapeutic goods intended for these conditions. The designation of Teduglutide (REVESTIVE) as an orphan drug under this Act applies to adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support, thereby catering to a specific medical need that affects a small patient population. This legislative action extends its jurisdictional reach across the entirety of Australia, ensuring that the designated therapeutic good is accessible and regulated uniformly throughout the country. The application of this Act does not specify exclusions or exemptions for this particular designation, although the broader regulatory framework may contain such provisions. The application and enforcement of the Therapeutic Goods Act 1989 can be further detailed and specified through subordinate instruments such as the Therapeutic Goods Regulations 1990, which provide additional guidelines and operational details for the Act’s implementation.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") and its associated Therapeutic Goods Regulations 1990 (the "Regulations") outline the framework for the regulation of therapeutic goods in Australia. The key provision of this legislation in the context of the designation of Teduglutide (REVESTIVE) as an orphan drug is found under section 16J of the Regulations. Specifically, subregulation 16J(2) of the Regulations provides the authority for the designation of a drug as an orphan drug. In this case, Dr. Anthony Gill, acting as the Delegate of the Secretary, has designated Teduglutide (REVESTIVE) as an orphan drug for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support (section 16J(2)). The designation of Teduglutide (REVESTIVE) as an orphan drug under the Regulations imposes specific obligations on the parties involved. The sponsor, Shire Australia Pty Limited, must ensure that the drug meets the criteria for orphan drug designation, including the requirement that the drug is intended for the treatment of a rare medical condition affecting fewer than 5,000 patients in Australia at any one time (Regulation 16J(1)). Furthermore, the sponsor must provide the necessary information and data to support the orphan drug designation, including evidence of the rarity of the condition and the intended use of the drug (Regulation 16J(3)). The sponsor is also responsible for ensuring that the drug complies with all other relevant provisions of the Act and Regulations. Breaching the requirements of the Act and Regulations can result in significant consequences. Under section 33 of the Act, a person who contravenes the Act or the Regulations may be guilty of an offence. The penalties for such offences can include substantial fines and, in some cases, imprisonment. For example, under section 33DA of the Act, a person who is found guilty of an offence involving the supply of therapeutic goods that do not comply with the Act or Regulations can be fined up to $220,000 for an individual or $1,100,000 for a body corporate. Additionally, section 33DC of the Act provides for civil penalties for breaches of the Act, including pecuniary penalties of up to $2.2 million for serious and repeated breaches. It is important for all parties involved in the regulation of therapeutic goods to be aware of these potential consequences and to ensure compliance with the Act and Regulations.